1HCY10 bottom-line green again: DAWH recently announced its 1HCY10 financial result, where the company posted PAT of PKR1,305mn (EPS: PKR10.84), compared to LAT of PKR615mn (LPS: PKR5.11) in the same period last year. Net sales down 11% YoY; Strong margins maintained: Gross profit took a dip by 11% YoY to PKR1,218mn, primarily attributable to 11% YoY decline in net sales on the back of lower volumes. Gross margins on the other hand stood firm at 41%.
97% YoY ↑ in profit from Associate & no impairment loss triggered profitability: Share of profit from Associate (Engro) stood at PKR1,096mn, up 97% on YoY basis. Combined with that, absence of impairment charge (impairment expense of PKR1,536mn in 1HCY09) was the major reason behind improved bottom-line.
Investment theme: At PKR165.5, the scrip is trading at 18.5% discount to its portfolio value (PKR203/share) at current market prices; let aside core operations, indicating room for further price appreciation.
Net sales down on lower volumes; Margins remain intact
Lower production due to gas curtailment, effective from 26th April, 2010 resulted in 24% YoY reduction in Urea sales to 178kT. Consequently, net sales of the company registered a decline of 11% YoY to PKR2,936mn during 1HCY10. With margins intact at 41% (having only Urea in its product-line enables the company to enjoy healthy margins), gross profit for the period decreased by 11% to PKR1,218mn. However, core earnings of the company were recorded at PKR401mn (PKR3.33/share) in 1HCY10 down from PKR537mn (PKR4.47/share) last year.
97% YoY ↑ in profit from Associate & no impairment triggered earnings
During the period under review, Engro’s earnings increased by more than two folds to PKR3,197mn (consolidated), which led DAWH’s share of profit to increase by almost 97% YoY to PKR1,096mn (DAWH holds around 125mn shares (38%) of Engro). Unlike last year, where the company booked PKR1,536mn impairment loss on its ‘available for sale’ investment (SNGPL & SEPCO). The company didn’t book any impairment expense during 1HCY10, resulting in a green bottom-line.
At yesterday’s closing prices, current market value of the company’s portfolio is PKR203/share. Given the strong portfolio value and anticipated recovery in offtake during 2HCY10, the scrip appears to be fairly attractive at current levels of PKR165.5/share as the market is currently pricing DAWH at 18.5% discount to its total portfolio (let aside core operations) which indicates room for further price appreciation.
Economic & Political News
High credit risk, increased NPLs key challenges: SBP
The SBP has said that heightened credit risk and increased portfolio of NPLs would be key challenges for the banking system in the coming quarters as flash floods are likely to influence banks’ performance, according to the quarterly performance review of the banking system released by the central bank. The asset base of the banking system increased at 5.4% to PKR6,782bn against a contraction during the previous quarter, corresponding to the established industry pattern for the second quarter. The SBP attributed the increase in asset base to growth in deposits, mainly occurred in the balances of the banks, inter-bank lending, government papers and public sector commodity finance, while lending to the private sector came down and moderated the overall growth in loan portfolio. The NPLs grew by 0.6% to PKR460bn from PKR457bn during the 1QCY10. The profit-after-tax (PAT) of PKR36bn for the 1HCY10 remained higher than the corresponding period last year.
The research analyst(s) denoted AC on the cover of this report, primarily involved in the preparation of this report, certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject companies/securities and (2) no part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.
The report has been prepared by Elixir Securities Pakistan (Pvt.) Ltd and is for information purpose only. The information and opinions contained herein have been compiled or arrived at based upon information obtained from sources, believed to be reliable and in good faith. Such information has not been independently verified and no guaranty, representation or warranty, expressed or implied is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as, an offer, or solicitation of an offer, to buy or sell any securities or other financial instruments.
Research Dissemination Policy
Elixir Securities Pakistan (Pvt.) Ltd. endeavors to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as mail, fax and/or email. Nevertheless, not all clients may receive the material at the same time.
Company Specific Disclosures
Elixir Securities Pakistan (Pvt.) Ltd. may, to the extent permissible by applicable law or regulation, use the above material, conclusions, research or analysis in which they are based before the material is disseminated to their customers. Elixir Securities Pakistan (Pvt.) Ltd., their respective directors, officers, representatives, employees and/or related persons may have a long or short position in any of the securities or other financial instruments mentioned or issuers described herein at any time and may make a purchase and/or sale, or offer to make a purchase and/or sale of any such securities or other financial instruments from time to time in the open market or otherwise. Elixir Securities Pakistan (Pvt.) Ltd. may make markets in securities or other financial instruments described in this publication, in securities of issuers described herein or in securities underlying or related to such securities. Elixir Securities Pakistan (Pvt.) Ltd. may have recently underwritten the securities of an issuer mentioned herein.
Other Important Disclosures
Foreign currency denominated securities is subject to exchange rate fluctuations which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. Foreign currency denominated securities is subject to exchange rate fluctuations which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.